CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
BMS-986036 +1 moredrug
Likely dose
BMS-986036 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03400163
NCT03400163Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis

Bristol-Myers Squibb·interventional·Posted Jan 17, 2018·Updated Feb 26, 2021

In Brief

A Phase 2 clinical trial evaluating BMS-986036 and Placebo for Non-Alcoholic Steatohepatitis. Completed, enrolled 3 participants across 2 sites.

Detailed Summary

The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Steatohepatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 17, 2018
Enrollment StartMay 8, 2015
Primary CompletionJan 18, 2017
Study CompletionJun 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.5 years ago

Interventions

BMS-986036drug

BMS-986036 20 mg QD

Placebodrug

Placebo QD